Cargando…

Case Report: Paliperidone Palmitate in the Management of Bipolar I Disorder With Non-compliance

Background: Medication non-adherence is prevalent in patients with bipolar disorder (BD). Long-acting injectable antipsychotics (LAIAs) are widely used to improve compliance with treatment. This study aimed to illustrate the effectiveness, compliance, and safety profile of once-monthly paliperidone...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Kanglai, Liao, Yingtao, Yang, Zhihua, Yang, Caishuang, Chen, Minhua, Wu, Xiuhua, Gan, Zhaoyu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Psychiatry
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7819884/ https://www.ncbi.nlm.nih.gov/pubmed/33488408 http://dx.doi.org/10.3389/fpsyt.2020.529672

Ejemplares similares

Are serum levels of inflammatory markers associated with the severity of symptoms of bipolar disorder?
por: Wu, Xiuhua, et al.
Publicado: (2023)

Tolerability profile of paliperidone palmitate formulations: A pharmacovigilance analysis of the EUDRAVigilance database
por: Cicala, Giuseppe, et al.
Publicado: (2023)

Rapid cycling bipolar disorder is associated with antithyroid antibodies, instead of thyroid dysfunction
por: Gan, Zhaoyu, et al.
Publicado: (2019)

Heterogeneity of psychosocial functioning in patients with bipolar disorder: Associations with sociodemographic, clinical, neurocognitive and biochemical variables
por: Ba, Zhengling, et al.
Publicado: (2022)

Patterns of persistence with pharmacological treatment among patients with current depressive episode and their impact on long-term outcome: a naturalistic study with 5-year follow-up
por: Li, Kanglai, et al.
Publicado: (2018)

Accidental Overdose of Paliperidone Palmitate
por: Ojimba, Chiedozie, et al.
Publicado: (2019)

Maintenance dose conversion between oral risperidone and paliperidone palmitate 1 month: Practical guidance based on pharmacokinetic simulations
por: Russu, Alberto, et al.
Publicado: (2018)

Paliperidone Palmitate for Schizoaffective Disorder: A Review of the Clinical Evidence
por: Greenberg, William M., et al.
Publicado: (2015)

Paliperidone Palmitate Every Three Months (PP3M) 2-Year Treatment Compliance, Effectiveness and Satisfaction Compared with Paliperidone Palmitate-Monthly (PP1M) in People with Severe Schizophrenia
por: Fernández-Miranda, Juan J., et al.
Publicado: (2021)

Differences of use between paliperidone palmitate 3 month and paliperidone palmitate 1 month in real practice, with psychotic patients
por: Escobedo-Aedo, P., et al.
Publicado: (2022)

Effects of Paliperidone Palmitate on Coagulation: An Experimental Study
por: Yılmaz, Enver Demirel, et al.
Publicado: (2014)

PM394. The outcome of paliperidone palmitate in schizophrenia
por: Ju, Po-Chung
Publicado: (2016)

Impairment in Emotional Intelligence May Be Mood-Dependent in Bipolar I and Bipolar II Disorders
por: Kuo, Shih-Yu, et al.
Publicado: (2021)

Real-life effectiveness of transitioning from paliperidone palmitate 1-monthly to paliperidone palmitate 3-monthly long-acting injectable formulation
por: Corbeil, Olivier, et al.
Publicado: (2022)

Partial compliance with long-acting paliperidone palmitate and impact on hospitalization: a 6-year mirror-image study
por: Pappa, Sofia, et al.
Publicado: (2020)

Sleep Disturbances in Pediatric Bipolar Disorder: A Comparison between Bipolar I and Bipolar NOS
por: Baroni, Argelinda, et al.
Publicado: (2012)

Management of Concurrent Bipolar I Disorder and Compulsive Sexual Behavior Disorder: A Case Report
por: Fiandor-Montesino, Jaclyn, et al.
Publicado: (2023)

Pharmacoeconomic analysis of paliperidone palmitate for treating schizophrenia in Greece
por: Einarson, Thomas R, et al.
Publicado: (2012)

Paliperidone palmitate-induced enuresis: a case report
por: Cruz, S., et al.
Publicado: (2022)

Paliperidone Palmitate Once-Monthly Injectable Treatment for Acute Exacerbations of Schizoaffective Disorder
por: Fu, Dong-Jing, et al.
Publicado: (2016)

Results from PSIPROSPER: A multicenter retrospective study to analyze the impact of treatment with paliperidone palmitate 1-month on clinical outcomes and hospital resource utilization in adult patients with schizophrenia in Portugal
por: Marques-Teixeira, João, et al.
Publicado: (2022)

Early Australian experience in the maintenance of schizophrenia management with 3-monthly paliperidone palmitate
por: Pai, Nagesh, et al.
Publicado: (2018)

Changes in thyroid function levels in female patients with first-episode bipolar disorder
por: Song, Xiuhua, et al.
Publicado: (2023)

The role of paliperidone extended release for the treatment of bipolar disorder
por: Marino, Jehan, et al.
Publicado: (2012)

Manic Symptoms during a Switch from Paliperidone ER to Paliperidone Palmitate in a Patient with Schizophrenia
por: Demirci, Kadir, et al.
Publicado: (2015)

Comparison of Hypomanic Symptoms Between Bipolar I and Bipolar II Disorders: A Network Perspective
por: Bai, Wei, et al.
Publicado: (2022)

Paliperidone palmitate injection for the acute and maintenance treatment of schizophrenia in adults
por: Kim, Shiyun, et al.
Publicado: (2012)

Paliperidone Palmitate-induced Urinary Incontinence: A Case Report
por: Karslıoǧlu, Ersin Hatice, et al.
Publicado: (2016)

Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia
por: Mathews, Maju, et al.
Publicado: (2019)

Paliperidone palmitate-induced facial angioedema: A case report
por: Srifuengfung, Maytinee, et al.
Publicado: (2020)

Alternative initiation regimen of paliperidone palmitate long-acting injectable
por: Menendez Gil, I.E., et al.
Publicado: (2022)

Cost-utility analysis of using paliperidone palmitate in schizophrenia in China
por: Luo, Rui, et al.
Publicado: (2023)

Clinical Study of Paliperidone Palmitate Long-Acting Injection Combined With Electroacupuncture in the Treatment of Methamphetamine Addicts
por: Chen, Yu, et al.
Publicado: (2021)

Role of paliperidone palmitate 3-monthly in the management of schizophrenia: insights from clinical practice
por: Lopez, Alicia, et al.
Publicado: (2019)

F230. COMPARISON OF PALIPERIDONE PALMITATE 3-MONTH AND PALIPERIDONE PALMITATE 1-MONTH FORMULATION FOR NEGATIVE SYMPTOMS IN SCHIZOPHRENIA: A PHASE 3 NON-INFERIORITY STUDY
por: Mathews, Maju, et al.
Publicado: (2018)

Comparative effectiveness study of paliperidone palmitate 6-month with a real-world external comparator arm of paliperidone palmitate 1-month or 3-month in patients with schizophrenia
por: Turkoz, Ibrahim, et al.
Publicado: (2023)

Predictors of transition from paliperidone palmitate 1 and 3 months (PP1M & PPP3M) to paliperidone palmitate 6 months (PP6M)
por: Escobedo-Aedo, P. J., et al.
Publicado: (2023)

Paliperidone Palmitate Once-Monthly Treatment in Recent Onset and Chronic Illness Patients With Schizoaffective Disorder
por: Bossie, Cynthia A., et al.
Publicado: (2017)

Communication and Handoff Errors Within Treatment-Resistant Bipolar I Disorder
por: Khan, Amna, et al.
Publicado: (2022)

Efficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophrenia
por: Zhang, Fan, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_r00r4danmidp60i0l7mtdvsicd